Friedreich’s ataxia (FA) is a rare, autosomal recessive neurodegenerative disease whose natural history and clinical characterization have made significant progress in recent decades. Nevertheless, there is still a lack of sensitive, objective biomarkers that both reliably reflect disease progression and are practicable for clinical studies. The TRACK-FA study, the largest multicenter, multimodal neuroimaging study in FA to date, is now making a decisive contribution. It shows that structural and functional imaging markers not only detect disease-relevant changes, but also correlate with clinical scales. This opens up new avenues for more precise diagnostics, the development of therapies and the shortening of study durations.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- From symptom to diagnosis
Multilocular cystic renal cell carcinoma (MCRCC)
- Shaping the Future with LLM & Co.
AI in Everyday Clinical Practice: Friend or Foe?
- Ulcerative colitis: current evidence on anti-inflammatory therapies
Remission induction and maintenance with biologics and JAK-i
- Bronchiectasis
New strategies against neutrophilic inflammation
- IBD in childhood
Pneumococcal vaccination without negative consequences
- Seborrheic Dermatitis in Adults and Adolescents
Current State of Knowledge and New Therapeutic Approaches
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Orthobiologics for knee osteoarthritis